Faecalibacterium prausnitzii Relating to Gastroenterology Diseases: Difference between revisions

From MicrobeWiki, the student-edited microbiology resource
No edit summary
 
(16 intermediate revisions by the same user not shown)
Line 1: Line 1:
==Section.==
==Introduction==
[[Image:Mrsa_magn_lg.jpg|thumb|300px|right|Magnified 20,000X, this colorized scanning electron micrograph (SEM) depicts a grouping of methicillin resistant <i>Staphylococcus aureus</i> (MRSA) bacteria. See PHIL 617 for a black and white view of this image. Phoro credit: [http://www.cdc.gov/ CDC.]]]
[[Image:FP.jpg|thumb|300px|right|Magnified 20,000X, this colorized scanning electron micrograph (SEM) depicts a grouping of methicillin resistant <i>Staphylococcus aureus</i> (MRSA) bacteria. See PHIL 617 for a black and white view of this image. Phoro credit: [http://www.cdc.gov/ CDC.]]]
<b>By Kayla Arone <br>
<b> By Kayla Arone </b>
<br>Faecalibacterium prausnitzii is a Gram-negative bacterium, non-sporeforming and extremely oxygen sensitive. This type of gut bacteria is the most abundant bacterium in the human gut, accounting for 5-15% of the total bacterial population in the gut. Decreased F. prausnitzii levels are observed in various forms of different inflammatory bowel disease (IBD), Crohn’s disease (CD), ulcerative colitis (UC), and colorectal cancer (CRC). <br><br>The insertion code consists of:
<br>
<br>Faecalibacterium prausnitzii is a Gram-negative bacterium, non-sporeforming and extremely oxygen sensitive. This type of gut bacteria is the most abundant bacterium in the human gut, accounting for 5-15% of the total bacterial population in the gut. It is very prevalent in human populations as it is detected in 85% of gut samples and F. prausnitzii is considered to be very prevalent in the GI track of humans. Levels of F. prausnitzii differ by age and gender as well with lower levels in women than men. Levels of F. prausnitzii can be first detected around 6-7 months of age and the abundance rises at around 2-3 years old suggesting that there are different evolutionary stages of F. prausnitzii. Decreased F. prausnitzii levels are observed in various forms of different inflammatory bowel disease (IBD), Crohn’s disease (CD), ulcerative colitis (UC), and colorectal cancer (CRC). <br><br>The insertion code consists of:
<br><b>Double brackets:</b> [[
<br><b>Double brackets:</b> [[
<br><b>Filename:</b> PHIL_1181_lores.jpg
<br><b>Filename:</b> PHIL_1181_lores.jpg
Line 24: Line 25:
<br> The repeated citation works like this, with a forward slash.<ref name=aa/>
<br> The repeated citation works like this, with a forward slash.<ref name=aa/>


==Section 1==
==Crohn's Disease==
Include some current research, with at least one figure showing data.<br>
Include some current research, with at least one figure showing data.<br>
<br>
<br>
Every point of information REQUIRES CITATION using the citation tool shown above.
Every point of information REQUIRES CITATION using the citation tool shown above.


==Section 2==
 
==Link between Faecalibacterium prausnitzii and Crohn’s Disease ==
Include some current research, with at least one figure showing data.<br>
Include some current research, with at least one figure showing data.<br>
<br>
<br>


==Section 3==
===Implications for Gut Homeostasis===
===Abundance of Bacteria In Crohn's Patients===
 
==Mechanisms and Interactions==
Include some current research, with at least one figure showing data.<br>
Include some current research, with at least one figure showing data.<br>
<br>
<br>


==Section 4==
===Anti-inflammatory Properties===
===Impact On the Gut Barrier===
===Interactions With the Immune System===
 
==Research Findings and Future Research==
 
===Studies on Faecalibacterium prausnitzii in Crohn’s Patients===
 
===Clinical Trials and Therapeutic Approaches===
 
 


==Conclusion==
==Conclusion==

Latest revision as of 15:59, 14 March 2024

Introduction

File:FP.jpg
Magnified 20,000X, this colorized scanning electron micrograph (SEM) depicts a grouping of methicillin resistant Staphylococcus aureus (MRSA) bacteria. See PHIL 617 for a black and white view of this image. Phoro credit: CDC.

By Kayla Arone

Faecalibacterium prausnitzii is a Gram-negative bacterium, non-sporeforming and extremely oxygen sensitive. This type of gut bacteria is the most abundant bacterium in the human gut, accounting for 5-15% of the total bacterial population in the gut. It is very prevalent in human populations as it is detected in 85% of gut samples and F. prausnitzii is considered to be very prevalent in the GI track of humans. Levels of F. prausnitzii differ by age and gender as well with lower levels in women than men. Levels of F. prausnitzii can be first detected around 6-7 months of age and the abundance rises at around 2-3 years old suggesting that there are different evolutionary stages of F. prausnitzii. Decreased F. prausnitzii levels are observed in various forms of different inflammatory bowel disease (IBD), Crohn’s disease (CD), ulcerative colitis (UC), and colorectal cancer (CRC).

The insertion code consists of:
Double brackets: [[
Filename: PHIL_1181_lores.jpg
Thumbnail status: |thumb|
Pixel size: |300px|
Placement on page: |right|
Legend/credit: Magnified 20,000X, this colorized scanning electron micrograph (SEM) depicts a grouping of methicillin resistant Staphylococcus aureus (MRSA) bacteria. Photo credit: CDC. Every image requires a link to the source.
Closed double brackets: ]]

Other examples:
Bold
Italic
Subscript: H2O
Superscript: Fe3+



Sample citations: [1] [2]

A citation code consists of a hyperlinked reference within "ref" begin and end codes.
To repeat the citation for other statements, the reference needs to have a names: "<ref name=aa>"
The repeated citation works like this, with a forward slash.[1]

Crohn's Disease

Include some current research, with at least one figure showing data.

Every point of information REQUIRES CITATION using the citation tool shown above.


Link between Faecalibacterium prausnitzii and Crohn’s Disease

Include some current research, with at least one figure showing data.

Implications for Gut Homeostasis

Abundance of Bacteria In Crohn's Patients

Mechanisms and Interactions

Include some current research, with at least one figure showing data.

Anti-inflammatory Properties

Impact On the Gut Barrier

Interactions With the Immune System

Research Findings and Future Research

Studies on Faecalibacterium prausnitzii in Crohn’s Patients

Clinical Trials and Therapeutic Approaches

Conclusion

References

  1. ↑ 1.0 1.1 Hodgkin, J. and Partridge, F.A. "Caenorhabditis elegans meets microsporidia: the nematode killers from Paris." 2008. PLoS Biology 6:2634-2637.
  2. ↑ Bartlett et al.: Oncolytic viruses as therapeutic cancer vaccines. Molecular Cancer 2013 12:103.



Authored for BIOL 238 Microbiology, taught by Joan Slonczewski,at Kenyon College,2024

Retrieved from "https://microbewiki.kenyon.edu/index.php?title=Faecalibacterium_prausnitzii_Relating_to_Gastroenterology_Diseases&oldid=164380"